Prihlásiť sa Zaregistrujte sa zadarmo

Trhová kapitalizácia spoločnosti NeuroVive Pharmaceutical AB

Aká je hodnota metriky Trhová kapitalizácia spoločnosti NeuroVive Pharmaceutical AB?

Hodnota metriky Trhová kapitalizácia spoločnosti NeuroVive Pharmaceutical AB je $15.23M

Aká je definícia metriky Trhová kapitalizácia?



Trhová kapitalizácia (Market cap) je trhová hodnota vydaných akcií obchodovanej spoločnosti a je rovná cene akcie v danom čase vynásobenej počtom kusov vydaných akcií.

As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.

Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.

The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.

Trhová kapitalizácia spoločností v sektore Miscellaneous sektor na LSE v porovnaní so spoločnosťou NeuroVive Pharmaceutical AB

Čomu sa venuje spoločnosť NeuroVive Pharmaceutical AB?

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Firmy s metrikou trhová kapitalizácia podobnou spoločnosti NeuroVive Pharmaceutical AB